NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

多發性硬化症的全球市場預測(2021-2027)

Multiple Sclerosis Market 2021-2027

出版商 Orion Market Research Pvt Ltd 商品編碼 1025358
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
多發性硬化症的全球市場預測(2021-2027) Multiple Sclerosis Market 2021-2027
出版日期: 2021年06月29日內容資訊: 英文
簡介

在預測期內,全球多發性硬化症市場預計將以約 2.5% 的複合年增長率增長。市場包括多發性硬化症患病率增加、FDA 對多發性硬化症治療和治療的批准增加、向口服藥物的轉變增加以及多發性硬化症治療管道的增加,這是增長的主要驅動力。提高認識計劃以教育人們瞭解多發性硬化症的藥物和治療方法,這也推動了市場增長。例如,2021 年 5 月,新基 (Celgene) 公司和美國多發性硬化症協會 (MSAA) 宣佈啟動一項全國性運動 MS Mind Shift,為多發性硬化症 (MS) 提供了新的視角。該活動旨在讓人們瞭解大腦在多發性硬化症 (MS) 中的重要作用,以及 MS 患者如何盡可能長時間保持大腦健康。此外,FDA 越來越多地批准主要市場進入者開發的多發性硬化症治療藥物,預計將為全球多發性硬化症市場的增長提供有利機會。例如,2020 年 9 月,艾伯維 (AbbVie) 公司從美國食品藥品監督管理局 (FDA) 獲得孤兒藥,用於治療脊髓損傷後患者的研究藥物 elezanumab (ABT-555)。

然而,昂貴的多發性硬化症治療藥物和診斷技術、治療的不良反應以及新興國家對多發性硬化症的低認識是阻礙市場增長的因素。由於供應鏈中斷和新藥生產暫停,全球多發性硬化症市場在很大程度上不受 COVID-19 的影響。

本報告對全球多發性硬化症市場進行調查和分析,並提供有關市場概況、市場決定因素、細分市場、競爭狀況、區域分析、主要公司等的系統信息。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和最新市場趨勢

第 3 章競爭形勢

  • 主要公司分析
    • 概述
    • 財務分析
    • SWOT 分析
  • 關鍵戰略分析
  • COVID-19 對大公司的影響

第 4 章市場決定因素

  • 增長因素
  • 抑制因素
  • 市場機會

第 5 章市場細分

  • 按類型劃分的全球多發性硬化症市場
    • 原發性進展型 MS
    • 進行性複發 MS
    • 復發緩解型 MS
    • 繼發性進展性多發性硬化症
  • 按診斷技術劃分的全球多發性硬化症市場
    • 核磁共振
    • 誘導電位測試
    • 腦脊液檢查
    • 其他
  • 按管理方法劃分的全球多發性硬化症市場
    • 注入
    • 口服製劑
    • 靜脈治療
  • 按藥物類別劃分的全球多發性硬化症市場
    • 免疫調節劑
    • 免疫抑製劑

第 6 章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他領域
    • 拉丁美洲
    • 中東/非洲

第 7 章公司簡介

  • AbbVie Inc.
  • AB Science SA
  • Active Biotech
  • Acorda Therapeutics, Inc.
  • Bayer AG
  • Biogen Inc.
  • BrainStorm Cell Ltd.
  • CELGENE CORPORATION
  • Forward Pharma A/S
  • Genentech, Inc
  • GW Pharmaceuticals Plc
  • Johnson & Johnson Services Inc.
  • Merck KGaA
  • Medday Pharmaceuticals GmbH
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics, Inc.
目錄
Product Code: OMR2023772

Global Multiple Sclerosis Market Size, Share & Trends Analysis Report By Types (PPMS, PRMS, RRMS, SPMS) By Diagnostics Technologies (MRI, Evoked Potential Test, Spinal Fluid Test, and Others) By Mode of Administration (Injectable Agents, Oral Agents, and Intravenous Therapy) By Drug Class (Immunomodulators, and Immunosuppressant) Forecast, 2021-2027

The global multiple sclerosis market is anticipated to grow at a CAGR of around 2.5% during the forecast period. The global multiple sclerosis market is driven by the rising prevalence of multiple sclerosis, the growing FDA approvals to the drugs and treatment for MS, increasing shift towards the oral drugs, and increase in the number of pipeline drugs for multiple sclerosis. The growing awareness programs to educate the people about the drugs and treatments of multiple sclerosis therapies are also fueling the market growth. For instance, in May 2021, Celgene Corporation and the Multiple Sclerosis Association of America (MSAA) announced the launch of a new campaign, MS MindShift, a national initiative that provides a new perspective on multiple sclerosis (MS). The campaign aims to educate about the critical role the brain plays in the disease and what people living with MS can do to keep their brain as healthy as possible, for as long as possible. Moreover, the rising FDA approvals to the drugs developed by the major market players for the treatment of multiple sclerosis is further expected to offer lucrative opportunities in the global multiple sclerosis market growth. For instance, in September 2020, AbbVie Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational treatment for patients following spinal cord injury.

Besides, these growth factors, the high cost of MS drugs and diagnostics technology, harmful effects of MS treatment, and lack of awareness about multiple sclerosis in emerging economies are some of the restraining factors that are hampering the market growth. The global multiple sclerosis market is hardly hit by the impact of COVID-19 due to the disruption in the supply chain and halt in the production of new drugs.

The global multiple sclerosis market is segmented based on types, diagnostics technologies, mode of administration, and drug class. Based on types, the global multiple sclerosis is categorized into primary progressive multiple sclerosis, progressive relapsing multiple sclerosis, relapsing remitting multiple sclerosis, and secondary progressive multiple sclerosis. Based on diagnostic technologies, the market is segregated into MRI, evoked potential test, spinal fluid test, and others. Similarly, based on the mode of administration, the global market for MS is breakdown into injectable agents, oral agents, and intravenous therapy. Among these, the oral agents segment dominated the market in 2020, and it is further expected to maintain its dominance in the multiple sclerosis market during the forecast period. Whereas according to drug class, the market is bifurcated into immunomodulators, and immunosuppressant.

Geographically the multiple sclerosis market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Amongst them, North America and Europe held the largest market share in the global market owing to the growing focus on awareness of multiple sclerosis. The high prevalence of multiple sclerosis in the U.S. has further boosted the growth of the multiple sclerosis market in North America. In 2017, approx. 1 million people living in multiple sclerosis in the US according to the National Multiple Sclerosis Society. The rapidly developing economies of Asia-Pacific are projected to witness the highest growth rate during the forecasted period. The growth in the Asia-Pacific market is backed by the growing awareness about the diagnosis and treatment options for multiple sclerosis issues coupled with the rising prevalence of neurological disorders within the regional countries. Along with it, efforts by government to increase the awareness about multiple sclerosis and funding programs by the government is helping in the growth of the Asia Pacific Multiple Sclerosis market.

Research Methodology

The market study of the global multiple sclerosis market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behaviour, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Multiple sclerosis Market Research and Analysis by Types

Global Multiple sclerosis Market Research and Analysis by Diagnostics Technologies

Global Multiple sclerosis Market Research and Analysis by Mode of Administration

Global Multiple sclerosis Market Research and Analysis by Drug Class

The Report Covers

Comprehensive research methodology of the global multiple sclerosis market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global multiple sclerosis market.

Insights about market determinants that are stimulating the global multiple sclerosis market.

Detailed and extensive market segments with the regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Multiple Sclerosis Industry
  • Recovery Scenario of Global Multiple Sclerosis Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Multiple Sclerosis Market, ByTypes
    • 5.1.1. Primary Progressive MS
    • 5.1.2. Progressive Relapsing MS
    • 5.1.3. Relapsing Remitting MS
    • 5.1.4. Secondary Progressive MS
  • 5.2. Global Multiple Sclerosis Market, By Diagnostics Technologies
    • 5.2.1. MRI
    • 5.2.2. Evoked Potential Test
    • 5.2.3. Spinal Fluid Test
    • 5.2.4. Others
  • 5.3. Global Multiple Sclerosis Market, By Mode of Administration
    • 5.3.1. Injectable Agents
    • 5.3.2. Oral Agents
    • 5.3.3. Intravenous Therapy
  • 5.4. Global Multiple Sclerosis Market, By Drug Class
    • 5.4.1. Immunomodulators
    • 5.4.2. Immunosuppressant

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World
    • 6.4.1. Latin America
    • 6.4.2. Middle East& Africa

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. AB Science SA
  • 7.3. Active Biotech
  • 7.4. Acorda Therapeutics, Inc.
  • 7.5. Bayer AG
  • 7.6. Biogen Inc.
  • 7.7. BrainStorm Cell Ltd.
  • 7.8. CELGENE CORPORATION
  • 7.9. Forward Pharma A/S
  • 7.10. Genentech, Inc
  • 7.11. GW Pharmaceuticals Plc
  • 7.12. Johnson & Johnson Services Inc.
  • 7.13. Merck KGaA
  • 7.14. Medday Pharmaceuticals GmbH
  • 7.15. Mylan N.V.
  • 7.16. Novartis AG
  • 7.17. Pfizer Inc.
  • 7.18. F. Hoffmann-La Roche Ltd.
  • 7.19. Sanofi S.A.
  • 7.20. Teva Pharmaceutical Industries Ltd.
  • 7.21. TG Therapeutics, Inc.

LIST OF TABLES

  • 1. GLOBAL MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY TYPES, 2020-2027 ($ MILLION)
  • 2. GLOBAL PRIMARY PROGRESSIVE MS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL PROGRESSIVE RELAPSING MSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL RELAPSING REMITTING MS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL SECONDARY PROGRESSIVE MS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TECHNOLOGIES, 2020-2027 ($ MILLION)
  • 6. GLOBAL MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TECHNOLOGIES, 2020-2027 ($ MILLION)
  • 7. GLOBAL MRI FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBALEVOKED POTENTIAL TEST FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL SPINAL FLUID TEST FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 10. GLOBAL OTHERS DIAGNOSTIC TECHNOLOGIES FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 11. GLOBAL MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY MODE OF ADMINISTRATION, 2020-2027 ($ MILLION)
  • 12. GLOBAL INJECTABLE AGENTS IN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL ORAL AGENTS IN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL INTRAVENOUS THERAPY IN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 16. GLOBAL IMMUNOMODULATORS IN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL IMMUNOSUPPRESSANT IN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 18. NORTH AMERICAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 19. NORTH AMERICAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BYTYPES,2020-2027 ($ MILLION)
  • 20. NORTH AMERICAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BYDIAGNOSTICS TECHNOLOGIES, 2020-2027 ($ MILLION)
  • 21. NORTH AMERICAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSISBYMODE OF ADMINISTRATION, 2020-2027 ($ MILLION)
  • 22. NORTH AMERICAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 23. EUROPEAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 24. EUROPEAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BYTYPES,2020-2027 ($ MILLION)
  • 25. EUROPEAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BYDIAGNOSTICS TECHNOLOGIES, 2020-2027 ($ MILLION)

26. EUROPEAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BYMODE OF ADMINISTRATION, 2020-2027 ($ MILLION

  • 27. EUROPEAN MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 28. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 29. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BYTYPES, 2020-2027 ($ MILLION)
  • 30. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BYDIAGNOSTICS TECHNOLOGIES,2020-2027 ($ MILLION)
  • 31. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY MODE OF ADMINISTRATION, 2020-2027 ($ MILLION)
  • 32. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)
  • 33. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 34. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY TYPES, 2020-2027 ($ MILLION)
  • 35. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS TECHNOLOGIES,2020-2027 ($ MILLION)
  • 36. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY MODE OF ADMINISTRATION, 2020-2027 ($ MILLION)
  • 37. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL MULTIPLE SCLEROSIS MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL MULTIPLE SCLEROSIS MARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL MULTIPLE SCLEROSIS MARKET, 2020-2027 (%)
  • 4. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE BYTYPES,2020 VS 2027 (%)
  • 5. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE BY DIAGNOSTICS TECHNOLOGIES,2020 VS 2027 (%)
  • 6. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE BY MODE OF ADMINISTRATION, 2020 VS 2027 (%)
  • 7. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE BY DRUG CLASS, 2020 VS 2027 (%)
  • 8. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL PRIMARY PROGRESSIVE MS MARKETSHARE BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL PROGRESSIVE RELAPSING MS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL RELAPSING REMITTING MS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL SECONDARY PROGRESSIVE MS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL MRI FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL EVOKED POTENTIAL TEST FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL SPINAL FLUID TEST FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL OTHERS DIAGNOSTIC TECHNOLOGIES FOR MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL INJECTABLE AGENTS IN MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 18. GLOBAL ORAL AGENTS IN MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL INTRAVENOUS THERAPY IN MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL IMMUNOMODULATORS IN MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 21. GLOBAL IMMUNOSUPPRESSANT IN MULTIPLE SCLEROSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
  • 22. US MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. CANADA MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. UK MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. ITALY MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. REST OF EUROPE MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. INDIA MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. CHINA MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)
  • 34. REST OF ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, 2020-2027 ($ MILLION)

35. REST OF THE WORLD MULTIPLE SCLEROSIS MARKET SIZE, 2021-2027($ MILLION